Eli Lilly and Company (NYSE: LLY) Q1 2022 earnings call dated Apr. 28, 2022
Corporate Participants:
Kevin Hern — Vice President of Investor Relations
David A. Ricks — Chairman and Chief Executive Officer
Anat Ashkenazi — Senior Vice President and Chief Financial Officer
Daniel M. Skovronsky — Senior Vice President and Chief Scientific and Medical Officer
Michael B. Mason — Senior Vice President and President, Lilly diabetes
Jacob Van Naarden — Senior Vice President, Chief Executive Officer of Loxo Oncology at Lilly and President, Lilly Oncolo
Anne E. White — Senior Vice President and President, Lilly Neuroscience
Analysts:
Louise Chen — Cantor — Analyst
Terence Flynn — Morgan Stanley — Analyst
Geoff Meacham — Bank of America — Analyst
Chris Schott — JPMorgan — Analyst
Andrew Simon Baum — Citigroup — Analyst
Seamus Fernandez — Guggenheim — Analyst
Alice Jennifer Nettleton — Wolfe Research — Analyst
Umer Raffat — Evercore — Analyst
Steve Scala — Cowen — Analyst
Vamil Divan — Mizuho — Analyst
Justin Burns — Barclays Bank — Analyst
Kerry Holford — Berenberg — Analyst
Evan Seigerman — BMO — Analyst
Chris Shibutani — Goldman Sachs — Analyst
Robyn Karnauskas — Truist Securities — Analyst
Presentation:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2022 Earnings Call. [Operator Instructions]
I would now like to turn the conference over to your host, Kevin Hern. Please go ahead.
Eli Lilly and Company (LLY) Q1 2022 Earnings Call Transcript